Abstract Number: 1596 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA)
Background/Purpose Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of RA, PsA and AS. Our previous…Abstract Number: 954 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose Approximately two-thirds of patients (pts) with psoriatic arthritis (PsA) experience progressive joint damage associated with varying degrees of disability. Here we present the 1-year…Abstract Number: 1354 • 2013 ACR/ARHP Annual Meeting
Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Background/Purpose: Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to…Abstract Number: 311 • 2013 ACR/ARHP Annual Meeting
Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis and Current Skin Involvement (PALACE 3)
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 3 compared the efficacy/safety of APR with placebo (PBO) in…Abstract Number: 1291 • 2013 ACR/ARHP Annual Meeting
COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic
Background/Purpose: Biologic treatment options such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there…Abstract Number: 317 • 2013 ACR/ARHP Annual Meeting
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Tender and Swollen Joint Counts In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…Abstract Number: 814 • 2013 ACR/ARHP Annual Meeting
Results Of a Randomised Controlled Trial Comparing Tight Control Of Early Psoriatic Arthritis (TICOPA) With Standard Care: Tight Control Improves Outcome
Background/Purpose: The aim of this study was to assess the impact of tight control of early psoriatic arthritis (PsA) in a randomised-controlled trial (RCT) using…Abstract Number: 319 • 2013 ACR/ARHP Annual Meeting
Secukinumab Shows Substantial Improvement In Both Psoriasis Symptoms and Physical Functioning In Moderate-To-Severe Plaque Psoriasis Patients With Psoriatic Arthritis: A Subanalysis Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Background/Purpose: Since interleukin (IL)-17A has a potential role in the pathogenesis and chronic inflammation of psoriatic disease, with similar pathways impacting skin and joints, strategies…Abstract Number: 815 • 2013 ACR/ARHP Annual Meeting
Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis (PALACE 2)
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. PALACE 2 compared the efficacy and safety of APR…Abstract Number: 107 • 2013 ACR/ARHP Annual Meeting
Duration Of Symptoms Before Diagnosis In Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Background/Purpose: Early diagnosis is important for the treatment of many rheumatic diseases. Little is known about the duration of symptoms before establishment of diagnosis, and if the…Abstract Number: 816 • 2013 ACR/ARHP Annual Meeting
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…Abstract Number: L4 • 2013 ACR/ARHP Annual Meeting
Apremilast in the Treatment of DMARD-Naïve Psoriatic Arthritis Patients: Results of a Phase 3 Randomized, Controlled Trial (PALACE 4)
Background/Purpose: Apremilast (APR), an oral PDE4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 4 compared APR with placebo (PBO) in DMARD-naïve patients (pts) with…Abstract Number: 818 • 2013 ACR/ARHP Annual Meeting
HLA-B*0801 Is Strongly Associated With Asymmetrical Sacroiliitis and HLA-B*27 With Symmetrical Involvement In Psoriatic Arthritis: Results Of a Long-Term Follow-Up Study Examining Clinical and Genetic Predictors Of Radiographic Sacroiliitis
Background/Purpose: Psoriatic arthritis (PsA) is characterised by involvement of both the appendicular and axial skeleton. Little is known about the clinical predictors of sacroiliitis (SI),…Abstract Number: L10 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 2-Year Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Background/Purpose: To evaluate long-term clinical/radiographic efficacy of subcutaneous UST 45/90 mg in patients with active psoriatic arthritis (PsA) through wk108 of the PSUMMIT 1 trial.…Abstract Number: 2478 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients With Early Spondyloarthritis. Results From a Specialized Consultation In a Clinical Hospital
Background/Purpose: The classification criteria for spondyloarthritis (SpA) intend to identify patients with this disease from the initial stages. The nonspecific characteristics, symptoms, signs, and additional…
- « Previous Page
- 1
- …
- 76
- 77
- 78
- 79
- 80
- 81
- Next Page »